Apigenin as a CD38 inhibitor in NAD metabolism models
Linked to CD38/NAD+ maintenance in mechanistic seed data.
This source is used to support the NAD Maintenance effect row in this compound monograph.
Durable audit route for one claim-like target. This page shows source-use records, assessment rationale, active challenges, revisions, and graph edges tied to the same target identity.
nad maintenance is included with provisional confidence because the record has direct section evidence but still needs endpoint-specific interpretation before it should be read as a strong clinical claim.
The assessment is anchored to the cited effect record rather than inferred from the compound name alone.
Sources considered for this assessment[1]
The row has an explicit structured record and citation mapping.
The current seed evidence does not yet carry the same detailed endpoint interpretation as Taurine.
The audit path is present; additional source interpretation can be added without changing the schema.
Linked to CD38/NAD+ maintenance in mechanistic seed data.
This source is used to support the NAD Maintenance effect row in this compound monograph.